ADC Therapeutics SA (ADCT)
Stock Price:
$33.58 USD
0.08 (0.24%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.37B |
| Revenue (ttm) |
2.34M |
| Net Income (ttm) |
-116.48M |
| Shares Out |
70.72M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 25, 2020 |
| Last Price |
$33.58 |
| Previous Close |
$33.50 |
| Change ($) |
0.08 |
| Change (%) |
0.24% |
| Day's Open |
34.00 |
| Day's Range |
33.16 - 34.57 |
| Day's Volume |
225,558 |
| 52-Week Range |
28.50 - 56.59 |
More Stats
| Market Cap |
2.37B |
| Enterprise Value |
2.26B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
70.72M |
| Float |
31.58M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
-1.83 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.17M |
| Short Ratio |
11.31 |
| Short % of Float |
5.59% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
1,014.80 |
| PB Ratio |
12.07 |
| Revenue |
2.34M |
| Operating Income |
-119.40M |
| Net Income |
-116.48M |
| Free Cash Flow |
-122.66M |
| Net Cash |
110.52M |
| Net Cash / Share |
1.56 |
| Gross Margin |
n/a |
| Operating Margin |
-5,102.52% |
| Profit Margin |
-4,977.90% |
| FCF Margin |
-5,241.71% |
| ROA |
-34.24% |
| ROE |
-126.46% |
| ROIC |
1,251.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
3 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
53.0
Current: $33.58
High
53.0
Target: 53.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 2.34 | 1.14 |
| Revenue Growth | 105.26% | - |
| Gross Profit | 2.34 | 1.14 |
| Operating Income | -119 | -126 |
| Net Income | -116 | -123 |
| Shares Outstanding | 66.87 | - |
| Earnings Per Share | -2.36 | -2.64 |
| Operating Cash Flow | -122 | -122 |
| Capital Expenditures | -0.36 | -0.94 |
| Free Cash Flow | -123 | -123 |
| Cash & Equivalents | 116 | 139 |
| Total Debt | 5.03 | - |
| Net Cash / Debt | 111 | 139 |
| Assets | 138 | 151 |
| Liabilities | 26.53 | 24.32 |
| Book Value | 111 | 126 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ADC Therapeutics SA |
| Country |
Switzerland |
| CEO |
Christopher John Martin |
Stock Information
| Ticker Symbol |
ADCT |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSE: ADCT |
| IPO Date |
May 15, 2020 |
Description
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.